

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1617

Coutre, Steven

Examiner: Jean-Louis, Samira

U.S. APPLICATION NO: 10/560669

DATE: March 23, 2007

FOR: New Pharmaceutical Uses of Staurosporine Derivatives

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,



George Dohmann
Attorney for Applicant
Reg. No. 33,593

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-7824
Date: August 6, 2009